Is a nasal spray an appropriate treatment for supraventricular tachycardia (SVT)?

Nasal Spray for SVT: Etripamil is Now an Appropriate First-Line Self-Treatment Option

Yes, a nasal spray (etripamil) is now an appropriate treatment for supraventricular tachycardia, specifically for acute termination of paroxysmal SVT (PSVT) in adults who can self-administer it after vagal maneuvers fail. This represents a significant advancement approved by the FDA in late 2025 1, 2.

Treatment Algorithm for Acute SVT

First-Line: Vagal Maneuvers

• Valsalva maneuver (bearing down for 10-30 seconds at 30-40 mmHg pressure) or carotid sinus massage (5-10 seconds after confirming no bruit) remain the initial intervention 3
• Success rate approximately 28% when switching between techniques 3
• Should be performed with patient supine

Second-Line: Self-Administered Etripamil Nasal Spray

If vagal maneuvers fail:

• Etripamil 70 mg intranasal spray can be self-administered at home
• Conversion rate: 60-70% within 30-60 minutes 4, 5, 6
• Median time to conversion: 15-18 minutes 4, 5, 6
• Can repeat 70 mg dose if symptoms persist after 10 minutes 4
• No test dose required before first use in real-world settings 4

Third-Line: Medical Facility Treatment

If etripamil fails or is unavailable:

• Intravenous adenosine (95% effective for AVNRT, 90-95% for AVRT) 3
• IV beta-blockers, diltiazem, or verapamil for hemodynamically stable patients 3
• Synchronized cardioversion for hemodynamically unstable patients 3

Key Advantages of Etripamil Nasal Spray

Etripamil fills a critical therapeutic gap between ineffective vagal maneuvers and the need for emergency department visits 7, 2. Traditional guidelines from 2015-2016 ACC/AHA/HRS [3-3] and 2019 ESC 8 did not include self-administered nasal therapies because they didn't exist yet.

Clinical Benefits:

• Patient autonomy: First non-parenteral, self-administered therapy for acute PSVT 1
• Rapid onset: 3 times faster than placebo (17 vs 53 minutes) 6
• Consistent efficacy: 75% of patients who treated 2 episodes had consistent response patterns 5
• Reduces healthcare utilization: Avoids emergency department visits 1, 2

Safety Profile:

• Adverse events are mild-to-moderate and primarily nasal-related 1, 4, 5:
  • Nasal discomfort (14-30%)
  • Nasal congestion (14%)
  • Rhinorrhea (12-13%)
  • Epistaxis (7%)
• No serious cardiac safety events within 24 hours of administration 5
• Side effects decrease with repeated use across multiple episodes 4
• No significant increase in serious adverse events compared to placebo 1

Important Caveats and Limitations

When NOT to Use Etripamil:

• Hemodynamically unstable patients require immediate cardioversion 3
• Pre-excited atrial fibrillation (WPW with AF) - use procainamide or ibutilide IV, NOT calcium channel blockers 3
• Systolic heart failure - avoid calcium channel blockers 3
• Wide-complex tachycardia of uncertain etiology - adenosine preferred for diagnosis 3

Population Limitations:

The role of etripamil in atrial fibrillation with rapid ventricular rates remains undefined and requires further post-marketing studies 1. This is specifically for atrioventricular nodal-dependent PSVT (AVNRT and orthodromic AVRT).

Comparison to "Pill-in-the-Pocket" Strategy

Traditional oral beta-blockers or calcium channel blockers taken at home have limited evidence support and are hampered by:

• Delayed onset of action (30-60+ minutes)
• Risk of hypotension and bradycardia
• Not robustly supported by guidelines 2

Etripamil's intranasal route provides faster absorption and more predictable pharmacokinetics than oral agents 1, 7.

Clinical Implementation

For appropriate candidates with recurrent PSVT, etripamil should be prescribed for at-home use with clear instructions:

1. Attempt vagal maneuvers first
2. Apply cardiac monitoring if available
3. Self-administer 70 mg etripamil intranasally
4. Can repeat dose after 10 minutes if needed
5. Seek emergency care if no conversion or symptoms worsen

This approach aligns with the modern goal of reducing emergency department utilization while maintaining patient safety 1, 2, representing a paradigm shift from the 2015-2016 guidelines that only recommended facility-based treatments [3-3].